Skip to main content
SpringerLink
Log in

Clinical Trials in Stroke Prevention in North America

  • Chapter
Clinical Trials in Neurology

  • 264 Accesses

Abstract

The randomized clinical trial has been applied in cerebral vascular disorders for nearly 30 years. The amount of research coming from Canada and the United States in the field of stroke prevention by biological agents and drugs is appropriate because of historical events. For example, heparin emerged from the laboratories of Dr. Charles Best at the University of Toronto [1], and Dr. Hugh Smythe working in Dr. Fraser Mustard’s laboratory at the same institution was the first to detect the platelet-inhibiting properties of any potentially therapeutic compound, sulfinpyrazone [2]. Within a year, Dr. Harvey Weiss in New York described the platelet-inhibiting action of aspirin [3]. It is somewhat artificial to divide the work of North Americans from that of Europeans in any field because of the cross-fertilization of ideas and collaborative studies. The first platelet-inhibiting drug to be put to the test of a clinical trial was dipyridamole. Its mode of action as a platelet antagonist was defined by a Canadian, Dr. Patricia Emmons, working in the Department of Hematology in Oxford [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Best CH. Preparation of Heparin its use in the first Clinical Case. Circulation 1959; Vol. 19: 79–86.

    Article  PubMed  CAS  Google Scholar 

  2. Smythe HA, Orygzlo MA, Murphy EA, et al. The effect of sulfinpyrazone (Anturan) on platelet economy and blood coagulation in man. Can Med Assoc J 1965; 92: 818–821.

    PubMed  CAS  Google Scholar 

  3. Weiss HJ, Aledort LM. Impaired platelet/connective-tissue reaction in man after aspirin ingestion. Lancet 1967; II: 495–497.

    Article  Google Scholar 

  4. Emmons PR, Harrison MJ, Honour AJ, Mitchell JR. Effect of a pyrimido pyrimidine derivative on thrombus formation in the rabbit. Nature 1965; 208: 255.

    Article  PubMed  CAS  Google Scholar 

  5. Mustard JF, Rowsell HC, Smythe HA, Senyi A, Murphy EA. The effect of sulfinpyrazone on platelet economy and thrombus formation in rabbits. Blood 1967; 29: 859–866.

    PubMed  CAS  Google Scholar 

  6. The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New Engl J Med 1978; 299: 53–59.

    Google Scholar 

  7. Dyken ML. Antiplatelet aggregating agents in transient ischemic attacks and the relationship of risk factors. In: Breddin K, Loew D, Uberla K, et al., editors. Prophylaxis of venous, peripheral, cardiac and cerebral vascular diseases with acetylsalicylic acid. Stuttgart: Schattauer Verlag, 1981: 141–148.

    Google Scholar 

  8. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8: 301–316.

    Article  PubMed  CAS  Google Scholar 

  9. The American-Canadian Co-operative Study Group. Persan-tine Aspirin Trial in cerebral ischemia: endpoint results. Stroke 1985; 16: 406–415.

    Google Scholar 

  10. Bousser MG, Eschwege E, Haguenau M, et al. AICLA’ controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5–14.

    Article  PubMed  CAS  Google Scholar 

  11. Guiraud-Chaumeil B, Rascol A, David JL, Boneu B, Clanet M, Bierme R. Prévention des récidives des accidents vasculaires cérébraux ischémiques par les anti-agrégants plaquettaires: résultats d’un essai thérapeutique contrólé de 3 ans. Rev Neurol (Paris) 1982; 138: 367–385.

    CAS  Google Scholar 

  12. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.

    Article  PubMed  CAS  Google Scholar 

  13. Enserink M. Fraud and ethics charges hit stroke drug trial. Science 1996; 274: 2004–2005.

    Article  PubMed  CAS  Google Scholar 

  14. Wilterdink JL, Easton JD. Dipyridamole Plus Aspirin in Cerebrovascular Disease. Arch Neurol 1999; 56: 1087–1092.

    Article  PubMed  CAS  Google Scholar 

  15. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989; 321: 501–507.

    Article  PubMed  CAS  Google Scholar 

  16. Hershey LA. Stroke prevention in women: role of aspirin versus ticlopidine. Am J Med 1991; 91: 288–292.

    Article  PubMed  CAS  Google Scholar 

  17. Grotta JC, Norris JW, Kamm B, TASS Baseline and Angiographic Data Subgroup. Prevention of stroke with ticlopidine: who benefits most? Neurology 1992; 42: 111–115.

    Google Scholar 

  18. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–1220.

    Article  PubMed  CAS  Google Scholar 

  19. Harbison JW. Ticlopidine versus aspirin for the prevention of recurrent stroke: analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 1992; 23: 1723 1727.

    Google Scholar 

  20. Oh PI, Lanctôt KL, Naranjo CA, Shear NH. Fatal aplastic anemia associated with ticlopidine therapy - approaches to an adverse drug reaction. Can J Clin Pharmacol 1995; 2: 1922.

    Google Scholar 

  21. Shear NH. Prevention of ischemic stroke [letter]. New Engl J Med 1995; 333: 460.

    PubMed  CAS  Google Scholar 

  22. Barnett HJM, Eliasziw M, Meldrum HE. Prevention of ischemic stroke [reply]. New Engl J Med 1995(August 17); 333: 460.

    Google Scholar 

  23. Bennett CL, Weinberg PF, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998; 128: 541–544.

    PubMed  CAS  Google Scholar 

  24. CAPRIE Steering Committee. A randomised, blinded, trial of cloppidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.

    Google Scholar 

  25. Tholl U, Anlauf M, Helmchen U. Clopidogrel and membranous nephropathy. Lancet 1999; 354: 1443–1444.

    Article  PubMed  CAS  Google Scholar 

  26. Chinnakotla S, Leone JP, Fidler ME, Hammeke MD, Tarantolo S. Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome in a Kidney/Pancreas Transplant Recipient. Transplantation 2000; 70: 550–552.

    Article  PubMed  CAS  Google Scholar 

  27. Moy B, Wang JC, Raffel GD, Marcoux II JP. Hemolytic Uremic Syndrome Associated with Clopidogrel. Arch Intern Med 2000; 160: 1370–1372.

    Article  PubMed  CAS  Google Scholar 

  28. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM. Thrombotic Thrombocytopenic Purpura Associated with Clopidogrel. N Engl J Med 2000; 342: 1773–1777.

    Article  PubMed  CAS  Google Scholar 

  29. Wood AJJ. Thrombotic Thrombocytopenic Purpura and Clopidogrel - A Need for New Approaches to Drug Safety. N Engl J Med 2000; 342: 1824–1826.

    Article  PubMed  CAS  Google Scholar 

  30. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. New Engl J Med 1989; 321: 129–135.

    Google Scholar 

  31. Steering Committee of the Physician’s Health Study Research Group. Special report: preliminary report: findings from the aspirin component of the ongoing Physicians’ Health Study. New Engl J Med 1988; 318: 262.

    Google Scholar 

  32. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266: 521–527.

    Article  PubMed  CAS  Google Scholar 

  33. Côté R, Battista RN, Abrahamowicz M, et al. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. Ann Intern Med 1995; 123: 649–655.

    PubMed  Google Scholar 

  34. Baker RN, Schwartz WS, Rose AS. Transient ischemic strokes: a report of a study of anticoagulant therapy. Neurology 1966; 16: 841.

    Article  Google Scholar 

  35. Pearce JMS, Gubbay SS, Walton JN. Long-term anticoagulant therapy in transient cerebral ischaemic attacks. Lancet 1965; I: 6.

    Article  Google Scholar 

  36. Taylor DW, Sackett DL, Haynes RB. Sample size for randomized trials in stroke prevention: how many patients do we need? Stroke 1984; 15: 968.

    Article  PubMed  CAS  Google Scholar 

  37. WARSS, APASS, PICSS, HAS and GENESIS Study Groups. The feasibility of a collaborative double-blind study using an anticoagulant. Cerebrovasc Dis 1997; 7: 100–112.

    Article  Google Scholar 

  38. Major ongoing clinical trials. Warfarin vs. aspirin for symptomatic intracranial disease (WASID). Stroke 2000; 31: 1479–1480.

    Google Scholar 

  39. Duke RJ, Block RF, Turpie AGG, et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: a randomized controlled trial. Ann Intern Med 1986; 105: 825.

    PubMed  CAS  Google Scholar 

  40. Cerebral Embolism Task Force. Cardiogenic brain embolism: the second report of the cerebral embolism task force. Arch Neurol 1989; 86: 727.

    Google Scholar 

  41. Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. New Engl J Med 1989; 320: 352.

    Article  PubMed  CAS  Google Scholar 

  42. Smith P, Arnesen H, Holme I. The effect of warfarin on mor 58. tality and reinfarction after myocardial infarction. New Engl J Med 1990; 323: 147.

    Article  PubMed  CAS  Google Scholar 

  43. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of 59. stroke in patients with nonrheumatic atrial fibrillation. New Engl J Med 1990; 323: 1505.

    Google Scholar 

  44. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349–355. 60.

    Google Scholar 

  45. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527–539.

    Google Scholar 

  46. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fib 61. rillation. New Engl J Med 1992; 327: 1406–1412. (Erratum, New Engl J Med 1993;343:687–691.)

    Google Scholar 

  47. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. 62. Lancet 1994; 343: 687–691.

    Google Scholar 

  48. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose war 63. farin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633–638.

    Google Scholar 

  49. Petersen P, Godtfredsen J, Boysen G. Placebo-controlled, ran 64. domized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The 65. Copenhagen AFASAK study. Lancet 1989; I: 175.

    Article  Google Scholar 

  50. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation 66. after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–1262.

    Google Scholar 

  51. Fields WS, Maslenikov V, Meyer JS, Hass WK, Remington RD, 67. Macdonald M. Joint study of extracranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical 68. treatment for transient cerebral ischemic attacks and cervical carotid artery lesions. JAMA 1970; 211: 1993–2003.

    Article  PubMed  CAS  Google Scholar 

  52. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in 69. symptomatic patients with high-grade carotid stenosis. New Engl J Med 1991; 325: 445–453.

    Google Scholar 

  53. European Carotid Surgery Trialists’ collaborative Group. MRC 70. European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet 1991; 337: 1235–1243.

    Article  Google Scholar 

  54. Chervu A, Moore WS. Carotid endarterectomy without arteri 71. ography. Ann Vasc Surg 1994; 8: 296–302.

    Article  PubMed  CAS  Google Scholar 

  55. Eliasziw M, Rankin RN, Fox AJ, Haynes RB, Barnett HJM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. Accuracy and prognostic consequences of ultrasonography in identifying severe carotid artery stenosis. Stroke 1995; 26: 1747–1752.

    Article  PubMed  CAS  Google Scholar 

  56. Buchan A, Gates P, Pelz D, Barnett HJM. Intraluminal throm 72. bus in the cerebral circulation. Stroke 1988; 19: 681–687.

    Article  PubMed  CAS  Google Scholar 

  57. Barnett HJM. Prospective randomized trial of symptomatic patients: results from the NASCET Study. In: Moore WS, editor. Surgery for cerebrovascular disease, 2nd ed. Philadelphia: Saunders, 1996: 537–539.

    Google Scholar 

  58. Hankey GJ, Warlow CP, Molyneuz AJ. Complications of cerebral angiography for patients with mild carotid territory ischaemia being considered for carotid endarterectomy. J Neuro! Neurosurg Psychiatry 1990; 53: 542–548.

    Article  CAS  Google Scholar 

  59. Barnett HJM, Gunton RW, Eliasziw M, Fleming L, Sharpe B, Gates P, Meldrum H, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. The Causes and Severity of Ischemic Stroke in Patients with Internal Carotid Artery Stenosis. JAMA 2000; 283 (11): 1429–1436.

    Article  PubMed  CAS  Google Scholar 

  60. Morgenstern LB, Fox AJ, Sharpe BL, Eliasziw M, Barnett HJM, Grotta JC for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group: The risks and benefits of carotid endarterectomy in patients with near occlusion of the carotid artery. Neurology 1997; 48: 911–915.

    Article  PubMed  CAS  Google Scholar 

  61. Inzitari D, Eliasziw M, Gates P, Sharpe B, Chan RKT, Meldrum HE, Barnett HJM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. The Causes and Risk of Stroke in Subjects with an Asymptomatic Internal Carotid Artery. N Engl J Med 2000 Jun 8; 342 (23): 1693–1700.

    Google Scholar 

  62. Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. JAMA 1991; 266: 3289–3294.

    Article  PubMed  CAS  Google Scholar 

  63. Mayo Asymptomatic Carotid Endarterectomy Study Group. Results of a randomized controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Mayo Clin Proc 1992; 67: 513–518.

    Google Scholar 

  64. Chambers BR, Norris JW. The case against surgery for asymptomatic carotid stenosis. Stroke 1984; 15: 964–967.

    Article  PubMed  CAS  Google Scholar 

  65. Hobson RW II, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. New Engl J Med 1993; 328: 221–227.

    Article  PubMed  Google Scholar 

  66. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421–1428.

    Google Scholar 

  67. Barnett HJM, Broderick JP. Carotid endarterectomy: Another wake-up call. Neurology 2000 (in press).

    Google Scholar 

  68. Hennerici M, Hulsbomer HB, Hefter H, Lemmerts D, Rautenberg W. Natural history of asymptomatic extracranial arterial disease: results of a long-term prospective study. Brain 1987; 110: 777–791.

    Article  PubMed  Google Scholar 

  69. Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. Stroke 1991; 22: 1485 1490.

    Google Scholar 

  70. Barnett HJM, Eliasziw M, Meldrum HE, Taylor DW. Do the facts and figures warrant a 10–fold increase in the performance of carotid endarterectomy on asymptomatic patients? Neurology 1996; 46: 603–608.

    Article  PubMed  CAS  Google Scholar 

  71. Taylor DW, Barnett HIM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, Silver FL, Hachinski V, Clagett GP, Barnes RW, Spence JD for the ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Low Dose and High Dose acetylsalicylic acid for Patients Undergoing Carotid Endarterectomy: a randomised controlled trial. Lancet 1999; 353: 2179–2184.

    Article  PubMed  CAS  Google Scholar 

  72. The EC/IC Bypass Study Group. Failure of extracranialintracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. New Engl J Med 1985; 313: 1191–1200.

    Google Scholar 

Download references

Authors
  1. H. J. M. Barnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Meldrum
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Eliasziw
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neuromuscular Unit, West London Neurosciences Centre, 1st Floor Pilot Wing, Charing Cross Hospital, Fulham Palace Road, W6 8RF, London, UK

    Roberto J. Guiloff MD, FRCP (Consultant Neurologist) (Consultant Neurologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag London

About this chapter

Cite this chapter

Barnett, H.J.M., Meldrum, H., Eliasziw, M. (2001). Clinical Trials in Stroke Prevention in North America. In: Guiloff, R.J. (eds) Clinical Trials in Neurology. Springer, London. https://doi.org/10.1007/978-1-4471-3787-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3787-0_18

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-856-0

  • Online ISBN: 978-1-4471-3787-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation